Glenmark Pharmaceuticals launches MINYM® GEL for the treatment of Moderate to Severe Acne

Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven global pharmaceutical company, has launched India's first topical Minocycline 4% Gel for the treatment of moderate to severe acne, under the brand name MINYM®. This is a potent antibacterial gel which exerts a strong anti-inflammatory action It also offers the lowest MIC90 (minimum Inhibitory Concentration at which it stops/prevents visible growth of 90% of isolates of bacteria) compared to the available topical antibacterial formulations.

Topical antibacterial formulations are some of the commonly used class of drugs for the treatment of acne. With no new topical formulations being launched over the last 30 years, there has been a gradual increase in resistance to the currently available topical antibacterial formulationsi ii. MINYM® Gel (Topical Minocycline 4% Gel) has been developed to address these growing concerns in treatment of acne and is safe to use in patients above 9 years of age.

Speaking at the launch, Alok Malik, Group Vice President & Head, India Formulations - Glenmark said, "Glenmark is a leader in the dermatology segment in India and has been at the forefront in providing access to the latest treatment options to the patients. We are proud to introduce the first topical Minocycline-based - MINYM® Gel, in India; proven for its potent antibacterial effect, anti-inflammatory action and lowest resistance, as a treatment option to patients aged 9 years and above suffering from acne."

Acne is an inflammatory skin disease affecting millions of people worldwide. It involves the pilosebaceous units and presents with comedones, papules and pustules and is affected by numerous risk factors. Acne usually begins in puberty and affects many adolescents and young adults. In a study conducted by Glenmark in 2020, on the prevalence of acne in Indiaiii, it was observed that 45 percent of the patients were males and 55 percent were females; and almost 72 percent of the patients were in the adolescent group whereas 27 percent patients were in the adult group.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 387.50 as compared to the previous close of Rs. 390.25. The total number of shares traded during the day was 34076 in over 1954 trades.

The stock hit an intraday high of Rs. 401.00 and intraday low of 386.25. The net turnover during the day was Rs. 13416084.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 MINYM GEL AcneTreatment